Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Published on 3/30/2026
AI Summary
Barclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.
Related News
Earnings
Tesla (TSLA) Reports Q2 Deliveries: Expected 406k Vehicles
Jun 28
Earnings
Vanguard Total Stock Market ETF (VTI) Averages 10% Annual Returns
Jun 28
Earnings
GameStop (GME) Reports $7.4 Billion Cash Amid Transformation Efforts
Jun 28
Earnings
Meta (META) Reports 33% Revenue Growth; Snap (SNAP) Hits $1.5B
Jun 28